IMS Capital Management grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,467 shares of the company’s stock after purchasing an additional 351 shares during the period. Johnson & Johnson makes up 1.2% of IMS Capital Management’s portfolio, making the stock its 19th biggest holding. IMS Capital Management’s holdings in Johnson & Johnson were worth $2,210,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of JNJ. Norges Bank acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $4,172,929,000. BlackRock Inc. raised its position in Johnson & Johnson by 2.6% during the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after acquiring an additional 4,982,885 shares in the last quarter. GQG Partners LLC raised its position in Johnson & Johnson by 1,109.4% during the fourth quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after acquiring an additional 3,627,424 shares in the last quarter. State Street Corp raised its position in Johnson & Johnson by 1.8% during the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after acquiring an additional 2,492,359 shares in the last quarter. Finally, National Bank of Canada FI bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $286,371,000. Institutional investors own 68.78% of the company’s stock.
Shares of JNJ stock opened at $173.01 on Wednesday. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $455.26 billion, a price-to-earnings ratio of 23.32, a PEG ratio of 3.35 and a beta of 0.66. The business’s 50-day moving average price is $177.75 and its 200-day moving average price is $173.07.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.61%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s payout ratio is presently 60.92%.
Several equities analysts recently weighed in on the stock. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. Sanford C. Bernstein lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $180.00 to $183.00 in a research report on Wednesday, March 16th. Raymond James lifted their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Finally, The Goldman Sachs Group lifted their price target on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $190.50.
In related news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider William Hait sold 29,699 shares of the stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the sale, the insider now owns 80,236 shares in the company, valued at $14,729,724.88. The disclosure for this sale can be found here. Insiders sold a total of 78,161 shares of company stock worth $13,895,302 over the last 90 days. Corporate insiders own 0.35% of the company’s stock.
Johnson & Johnson Profile (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- SeaWorld Entertainment Stock Can be Caught on the Downdraft
- Buy the Dip in These 3 Mid-Caps
- Lululemon Stock Bestows a Buying Opportunity
- ABM Industries, A Clean Play For Dirty Economic Times
- Should Silver Stocks Be A Part Of Your Portfolio?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.